Clinical Trials Logo

Melanoma (Skin) clinical trials

View clinical trials related to Melanoma (Skin).

Filter by:
  • Active, not recruiting  
  • « Prev · Page 4

NCT ID: NCT00003641 Active, not recruiting - Melanoma (Skin) Clinical Trials

High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma

Start date: March 25, 1999
Phase: Phase 3
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.

NCT ID: NCT00002845 Active, not recruiting - Melanoma (Skin) Clinical Trials

Interleukin-2 in Treating Patients With Metastatic Melanoma

Start date: September 1995
Phase: Phase 2
Study type: Interventional

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: Phase II trial to study the effectiveness of interleukin-2 in treating patients who have metastatic melanoma.

NCT ID: NCT00002817 Active, not recruiting - Melanoma (Skin) Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Start date: April 1996
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Vaccines may make the body build an immune response to kill melanoma cells. PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients with metastatic melanoma.

NCT ID: NCT00002781 Active, not recruiting - Melanoma (Skin) Clinical Trials

Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma

Start date: April 1996
Phase: Phase 1
Study type: Interventional

RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. PURPOSE: Phase I trial to study the effectiveness of boron neuron capture therapy in treating patients with stage III melanoma.

NCT ID: NCT00002767 Active, not recruiting - Melanoma (Skin) Clinical Trials

Interferon Alfa With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma

Start date: January 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells.Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether melanoma vaccine plus interferon alfa is more effective than interferon alfa alone in treating patients with metastatic melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of interferon alfa with or without vaccine therapy in treating patients with metastatic melanoma.

NCT ID: NCT00002763 Active, not recruiting - Melanoma (Skin) Clinical Trials

High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma

Start date: April 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not known whether giving high-dose or low-dose interferon alfa is more effective than no further therapy in treating patients with stage III melanoma. PURPOSE: Randomized phase III trial to compare the effectiveness of high- or low-dose interferon alfa with that of no further therapy following surgery in treating patients who have stage III melanoma.

NCT ID: NCT00002455 Active, not recruiting - Breast Cancer Clinical Trials

Immunotherapy After Surgery in Treating Patients With Breast Cancer, Colon Cancer, or Melanoma

Start date: April 1971
Phase: Phase 3
Study type: Interventional

RATIONALE: Immunotherapy uses different ways to stimulate the immune system and stop cancer cells from growing. Immunotherapy biological extracts may be useful as adjuvant therapy in treating patients who have had surgery for breast cancer, colon cancer, or melanoma. PURPOSE: Phase III trial to study the effectiveness of Corynebacterium granulosum extract as maintenance immunotherapy following surgery in treating patients with breast cancer, colon cancer, or melanoma.